Literature DB >> 11521118

Current perspectives on benefits and risks of hormone replacement therapy.

R T Burkman1, J A Collins, R A Greene.   

Abstract

Hormone replacement therapy with estrogen alone or with added progestin relieves menopausal symptoms and physical changes associated with depleted endogenous estrogen levels. Estrogen replacement has also demonstrated a clear benefit in the prevention of osteoporosis. Hormone replacement therapy with added progestin maintains spinal bone density, protects against postmenopausal hip fractures, and provides these benefits even when therapy is started after age 60. More recently, additional benefits have emerged. Current estrogen and hormone replacement therapy users have a 34% reduction in the risk of colorectal cancer and a 20% to 60% reduction in the risk of Alzheimer's disease. Until recently, the body of evidence indicated that hormone replacement therapy with estrogen only reduced cardiovascular disease risk by 40% to 50% in healthy patients; whether the findings of 3 ongoing trials will change this conclusion is pending availability of the final results. The many benefits of estrogen and hormone replacement therapy must be weighed against a slight increase in the risk of breast cancer diagnosis with use for 5 or more years, but which disappears following cessation of therapy. Overall, estrogen and hormone replacement therapy improves the quality of life and increases life expectancy for most menopausal women.

Entities:  

Mesh:

Year:  2001        PMID: 11521118     DOI: 10.1067/mob.2001.117414

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

Review 1.  Estrogen replacement therapy and female athletes: current issues.

Authors:  D C Cumming; C E Cumming
Journal:  Sports Med       Date:  2001       Impact factor: 11.136

Review 2.  Hormonal replacement therapy.

Authors:  Regine Sitruk-Ware
Journal:  Rev Endocr Metab Disord       Date:  2002-09       Impact factor: 6.514

3.  Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study.

Authors:  Joshua A Roth; Ruth Etzioni; Teresa M Waters; Mary Pettinger; Jacques E Rossouw; Garnet L Anderson; Rowan T Chlebowski; Joann E Manson; Mark Hlatky; Karen C Johnson; Scott D Ramsey
Journal:  Ann Intern Med       Date:  2014-05-06       Impact factor: 25.391

Review 4.  Sexual dysfunction in the older woman: an overview of the current understanding and management.

Authors:  Kathleen E Walsh; Jennifer R Berman
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

5.  EFFECTS OF EXERCISE ON MIR-29 AND IGF-1 EXPRESSION AND LIPID PROFILE IN THE HEART OF OVARIECTOMIZED RAT.

Authors:  P Habibi; A Alihemmatti; M Alipour; A Nourazar; H Yousefi; S Andalib; N Ahmadiasl
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Apr-Jun       Impact factor: 0.877

6.  Schisandrae Fructus Reduces Symptoms of 4-Vinylcyclohexene Diepoxide-Induced Ovarian Failure in Mice.

Authors:  Dasom Shin; Jinhee Ha; Seong Bin Hong; Geun-Hyung Kang; Deok-Sang Hwang; Hyunsu Bae
Journal:  Evid Based Complement Alternat Med       Date:  2017-05-11       Impact factor: 2.629

Review 7.  Tissue selective estrogen complex (TSEC): a review.

Authors:  James H Pickar; Matthieu Boucher; Diana Morgenstern
Journal:  Menopause       Date:  2018-09       Impact factor: 2.953

8.  Effects of six weeks of resistance-endurance training on microRNA-29 expression in the heart of ovariectomised rats.

Authors:  Morteza Jourkesh; Rahman Soori; Conrad P Earnest; Lamia Mirheidari; Ali Asghar Ravasi; Stephen R Stannard; Matias Monsalves-Alvarez
Journal:  Prz Menopauzalny       Date:  2018-12-30

Review 9.  Postmenopausal syndrome.

Authors:  Pronob K Dalal; Manu Agarwal
Journal:  Indian J Psychiatry       Date:  2015-07       Impact factor: 1.759

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.